ChinaDaily Briefs

Daily Brief China: Alibaba Group Holding , China Tourism Group Duty Free Corp Ltd, Meituan, Hong Kong Hang Seng Index, Bilibili Inc, China Jinmao Holdings, Hansoh Pharmaceutical, Xiamen International Investment and more

In today’s briefing:

  • Ant Group’s $6.0bn Buyback Move Casts Doubt on IPO Prospects
  • China Tourism Duty Free Corp (601888. CH): Is Now Good Time for Bottom-Fishing?
  • China Internet Weekly (10Jul2023): Meituan, Alibaba, Ant Group, Tencent
  • EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades-Taking a Breather
  • [Bilibili (BILI US, SELL, TP US$12.3) TP Change]: The Launch Of “Uma Musume” May Face More Delay
  • Morning Views Asia: China Jinmao Holdings, Sunny Optical Technology Group, Tata Motors ADR
  • Hansoh Pharmaceutical (3692.HK)- Positive Growth in 2023, but Valuation Turning Point Hasn’t Arrived
  • Xiamen International Investment Pre-IPO Tearsheet
  • EQD | Hang Seng Index (HSI) WEEKLY Looking for Short-Term Direction


Ant Group’s $6.0bn Buyback Move Casts Doubt on IPO Prospects

By Oshadhi Kumarasiri

  • China’s regulators on Friday imposed Ant Financial Services Group (6688 HK) with a fine of RMB 7.12bn. A day later, Ant Group unveiled a share buyback program worth $6bn.
  • The last time media created a positive narrative around Ant Group was in January 2023 when Jack Ma relinquished control of the company.
  • However, the media excitement was short-lived as Alibaba Group Holding (9988 HK)‘s share price quickly resumed a downward trend after rising by around 22%.

China Tourism Duty Free Corp (601888. CH): Is Now Good Time for Bottom-Fishing?

By Eric Chen

  • CDF’s 1H23 preliminary results suggest that business recovery remains on track. Voices of bottom-fishing are getting louder as free fall in its share price already erased 50% market cap YTD.
  • We believe the dynamics have fundamentally changed compared to three years ago when CDF was the stock market darling. Investors need be aware of the anchoring effect in making decisions.
  • Moderate growth, pressured margin and contracted valuation multiple will be the new reality facing investors of the stock in our view. Wait for better entry point.

China Internet Weekly (10Jul2023): Meituan, Alibaba, Ant Group, Tencent

By Ming Lu

  • Meituan’s food delivery has taken 20% of the Hong Kong market share in its first month’s operations.
  • The authorities suggests that they will not further restrict financial apps such as AliPay of Ant Group.
  • Tencent’s WeChat Pay charged a money transfer commission, but it exempted university campus the next day.

EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades-Taking a Breather

By Simon Harris

  • Weekly summary of vol changes and moves across Global Markets
  • Analysing ATM volatility and skew changes over the last 5 days
  • We suggest a few trades to take advantage of the implied vol surfaces

[Bilibili (BILI US, SELL, TP US$12.3) TP Change]: The Launch Of “Uma Musume” May Face More Delay

By Shawn Yang

  • We cut our revenue estimations for 2H23, mainly due to increased uncertainty surrounding the launch of “Uma Musume.” 
  • We also lower our estimations for live streaming due to concerns about macro factors. We slightly raise our estimations for BILI’s advertising business…
  • …as we anticipate that it will benefit from gaming and e-commerce. Our rev./non-GAAP net income are 1.0% and (6.4%) vs cons in 2Q23. Cut TP to $12.3, maintaining “Sell” rating.

Morning Views Asia: China Jinmao Holdings, Sunny Optical Technology Group, Tata Motors ADR

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Hansoh Pharmaceutical (3692.HK)- Positive Growth in 2023, but Valuation Turning Point Hasn’t Arrived

By Xinyao (Criss) Wang

  • VBP would continue to have an impact on Hansoh’s generic drug business in 2023.Such negative impact would gradually fade from 2024 as big varieties have all been included in VBP.
  • The core difference between Hansoh and Hengrui is that someone similar to Zhang Lianshan’s role arrived late, resulting in a slower start and weaker overall framework for innovation drug business.
  • Hansoh Pharmaceutical (3692 HK) is still in the process of business transformation. Before the harvest time of innovative drug pipeline comes, Hansoh’s valuation growth would still be a long-term story.

Xiamen International Investment Pre-IPO Tearsheet

By Ethan Aw

  • Xiamen International Investment (1567256D HK) is looking to raise up to US$1.3bn in its upcoming HK IPO. The deal will be run by CICC, Citic Securities, Huatai and Industrial Securities.
  • Xiamen International Investment (XII) is an integrated financial services group based in China’s Greater Bay Area. 
  • The Group has two commercial banks headquartered in Hong Kong and Macau, respectively and operates through its two banks Chiyu Banking Corporation (CYB) and Luso International Banking (LIB).

EQD | Hang Seng Index (HSI) WEEKLY Looking for Short-Term Direction

By Nico Rosti

  • The Hong Kong Hang Seng Index (HSI INDEX) has been in a downtrend since January 2018. Long-term direction unclear, but the WEEKLY period is mildly OVERSOLD, it may bounce soon.
  • The case for a LONG trade is valid if the market does not fall > 2 consecutive weeks from June 30th’s Close (18916.43). High-probability LONG trades from 17786.
  • SHORT trade strategy possible but requires patience: if the market rises, it could rise for 2-3 weeks, based on MRM’s pattern readings. Better wait and short that scenario, not earlier.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars